



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
SERVING THE NATION SINCE 1950

भारतीय आयुर्विज्ञान अनुसंधान परिषद
स्वास्थ्य अनुसंधान विभाग स्वास्थ्य एवं परिवार
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

No. RTI/2020/ECD-I

Dated: 21.01.2021

To,

Sh. Mohit Khatana,
Advocate
Chamber No. 14,
Gate Number 2, District Court,
Gurugram Haryana - 122001

Subject: - "Request for information under RTI act-2005"

Sh. Mohit Khatana,

This communication is in response to your RTI application Reg. No., DTGHS/R/E/20/00788, dated: 16/12/2020, received from Ministry of Health & Family Welfare, Letter No. Z.28016/279/2020-EMR, dated: 11/01/2021, seeking information under RTI Act-2005.

Attached please find the relevant information as available with ICMR.

Yours faithfully,

(Dr. Nivedita Gupta)
Scientist F & CPIO

Copy to: - **Dr. Yogesh**, CPIO & CMO (EMR), Medical Relief Cell, MoH&FW, Directorate General of Health Services, Nirman Bhavan, New Delhi - 110011.

RTI Cell, ICMR, New Delhi. (19/CP-RTI/2021/ICMR)

वी रामलिंगस्वामी भवन, पोस्ट बॉक्स नं. 4911
अंसारी नगर, नई दिल्ली - 110 029, भारत
V. Ramalingaswami Bhawan, P.O. Box No. 4911,
Ansari Nagar, New Delhi - 110 029, India

Tel: +91-11-26588895 / 26588980 / 26589794
+91-11-26589336 / 26588707
Fax: +91-11-26588662 | icmr.nic.in

**INDIAN COUNCIL OF MEDICAL RESEARCH
DIVISION OF EPIDEMIOLOGY AND COMMUNICABLE DISEASES**

Replies _

1. This information is not available with the Indian Council of Medical Research. The requested information will be available on the product inserts of COVID-19 vaccines.
2. Information on accuracy of COVID-19 RTPCR test is available at:
 - A. <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01810-8>
 - B. <https://wellcomeopenresearch.org/articles/5-254>
3. This list of institutes validating testing kits in India and the list of approved RTPCR kits is available at: <https://www.icmr.gov.in/ckitevaluation.html> .
Information beyond this is not available in the public domain.
4. Interim guidance on the use of masks in the context of COVID-19 has been published by WHO on December 1, 2020. The information is available at: [https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-\(2019-ncov\)-outbreak](https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak)
5. Size of SARS-CoV-2 virus: Diameter 60-140 nm. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092803/>
Size of *M.tuberculosis*: 0.2 to 0.6 µm by 1 to 10 µm. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988623/>
Size of Influenza virus particle is around 70 µm. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2135376/>
6. R_0 for SARS-CoV-2 has been found to range from 1.00 to 4.55. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363110/>
 R_0 for *M.tuberculosis* has been found to range from 0.24 to 4.3. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092233/>
 R_0 for H1N1 influenza has been found to range from 1.4 to 1.6. This information is available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735127/>
7. The clinical management protocol for COVID-19 patients in India is available at: <https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf>
8. This information is not available with the Indian Council of Medical Research.
9. This information is not available with the Indian Council of Medical Research.
10. This information is not available with the Indian Council of Medical Research.
11. Information on fetal bovine serum and its use in medicine is available at: <https://bioresourcesbioprocessing.springeropen.com/articles/10.1186/s40643-015-0063-7>
12. Overall efficacy of ChAdOx1 nCoV-19 (Covishield) was 70.4%, according to interim trial results from Brazil, South Africa and UK. This information is available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32661-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext)
13. This information is available at: <https://www.mohfw.gov.in/pdf/FAQsonCOVID19VaccineDecember2020.pdf>
14. This information is available at: <https://www.mohfw.gov.in/pdf/FAQsonCOVID19VaccineDecember2020.pdf>